News | March 14, 2024
Cureskin secures US$ 20 million in Series B funding
Cureskin aims to disrupt the large and growing skin and hair care industry in India
Cureskin aims to disrupt the large and growing skin and hair care industry in India
Anand is committed to leading the company's continued commitment to driving innovation in Health Care through the utilization of Digital transformation, AI and LLM
PREVENAR offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the 20 serotypes responsible for the majority of currently circulating pneumococcal disease in the EU and globally
Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals
This partnership marks a significant step for the Company towards establishing renewable energy power generation using hybrid open excess through solar and wind sources
It is the first autotaxin inhibitor to be investigated in cancer patients
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
AbCellera will receive an upfront payment and is eligible to receive additional milestone payments
Vision loss due to Glaucoma can be prevented if it is detected and treated early
Subscribe To Our Newsletter & Stay Updated
